{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Evaluation of New Active Substance Status for Biological Products in the EU",
    "url": "https://www.lexblog.com/2022/12/21/evaluation-of-new-active-substance-status-for-biological-products-in-the-eu/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-ADHM3SBK",
        "url": "https://www.lexblog.com/lib/ADHM3SBK/"
    },
    "datePublished": "2022-12-21T07:30:06-05:00",
    "dateModified": "2022-12-21T04:30:22-05:00",
    "author": {
        "@type": "Person",
        "name": "Arnold & Porter, Alexander Roussanov, Sofia Wilson"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Arnold & Porter Kaye Scholer LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "BioSlice Blog",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://www.biosliceblog.com/?p=3172",
    "sourceStability": "may-move"
}